Search results
Showing 7996 to 8010 of 8905 results
Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)
This evidence summary has been updated and replaced by NICE guideline NG101.
Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)
This evidence summary has been updated and replaced by NICE technology appraisal guidance 664.
This evidence summary has been updated and replaced by NICE guideline 115.
Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)
This evidence summary has been updated and replaced by NICE guideline NG201.
This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
Chronic obstructive pulmonary disease: beclometasone, formoterol and glycopyrronium (Trimbow) (ES17)
This evidence summary has been updated and replaced by NICE guideline 115.
This evidence summary has been withdrawn because the product is no longer available in the UK.
Antimicrobial prescribing: nebulised liposomal amikacin (ES36)
This evidence summary has been withdrawn. An NHS England clinical commissioning policy on nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex is available.
This guidance has been updated and replaced by NICE HealthTech guidance 623.
This guidance has been updated and replaced by NICE HealthTech guidance 622.
This evidence summary has been withdrawn following the MHRA pregnancy-prevention advice issued for women and men taking mycophenolate.
Interstitial cystitis: oral pentosan polysulfate sodium (ESUOM43)
This guidance has been updated and replaced by NICE technology appraisal guidance 610.
Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)
This evidence summary has been updated and replaced by NICE guideline NG117.
This evidence summary has been updated and replaced by NICE guideline NG97.
This evidence summary has been updated and replaced by NICE evidence summary: new medicines 61.